An amended ownership statement for Evelyn D'An, a director of Matinas BioPharma Holdings, Inc. (NYSE:MTNB), was filed on November 9, 2026, correcting an administrative error in the previously reported exercise price of a stock option granted on November 6, 2026.

Key Highlights

  • Amendment purpose: The filing was submitted solely to correct an administrative error in the exercise price of a stock option originally reported on November 6, 2026.
  • Corrected exercise price: The stock option exercise price is stated as $1.19 per share in the amended filing.
  • Option size: The grant covers the right to purchase 5,000 shares of Matinas BioPharma common stock, par value $0.0001 per share.
  • Grant plan: The option was issued pursuant to the issuer's 2025 Equity Incentive Plan.
  • Vesting terms: The option vests in full on the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the Plan, subject to continued service.
  • Expiration date: The option expires on November 6, 2036, according to the filing.
  • Price of derivative security: The filing lists the price of the derivative security as $0.

Matinas BioPharma Director Option Grant Amended to Fix Exercise Price

Matinas BioPharma Holdings, Inc., a biopharmaceutical company whose common stock trades on the NYSE under the ticker MTNB, was the subject of an amended Section 16 ownership statement filed by director Evelyn D'An on November 9, 2026. According to the filing, the amendment was made "solely to correct an administrative error in the exercise price of the Stock Option previously reported in Column 2 of Table II" of the original November 6, 2026 filing. The corrected exercise price is $1.19 per share.

The underlying transaction, as described in the filing, was a grant on November 6, 2026 of a stock option to purchase 5,000 shares of Matinas BioPharma common stock. The option was granted under the company's 2025 Equity Incentive Plan. The filing states that the option will vest in full upon the earlier of the one-year anniversary of the grant date or a "Change in Control" as defined by the Plan, in each case subject to D'An's continued service through the applicable vesting date. The option is classified as a direct holding and is set to expire on November 6, 2036. Following the reported transaction, D'An beneficially owns 5,000 derivative securities of this type, according to the filing.

The amended statement was signed by Jerome D. Jabbour as attorney-in-fact for Evelyn D'An and dated November 9, 2026. No changes to the number of shares, vesting schedule, or expiration date were indicated; the sole correction pertains to the exercise price figure reported in the original filing.

What Was Disclosed

The amended filing corrects the exercise price on a 5,000-share stock option granted to Matinas BioPharma director Evelyn D'An on November 6, 2026, under the 2025 Equity Incentive Plan, setting the price at $1.19 per share and expiration at November 6, 2036.